Related references
Note: Only part of the references are listed.PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas
Tianjin Yi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Erica L. Gornstein et al.
CLINICAL BREAST CANCER (2018)
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Laura Lupini et al.
SCIENTIFIC REPORTS (2018)
Breast cancer risk and clinical implications for germline PTEN mutation carriers
Joanne Ngeow et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
Thales C. Nepomuceno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
C. Winter et al.
ANNALS OF ONCOLOGY (2016)
Homologous recombination deficiency and ovarian cancer
Jonathan A. Ledermann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
Stephen Murata et al.
BIOMED RESEARCH INTERNATIONAL (2016)
BRACAnalysis CDx as a companion diagnostic tool for Lynparza
Camille C. Gunderson et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Share Paper
